Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Olaparib

EU orphan designation number: EU/3/07/501   
Active ingredient: Olaparib
Indication: Treatment of ovarian cancer
Sponsor: AstraZeneca AB
SE-151 85 Södertälje, Sverige
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Lynparza on 16/12/2014 with the number EU/1/14/959

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
10/12/2007 Orphan designation EMEA/OD/063/07 (2007)6258 of 06/12/2007
17/06/2014 Change of name and/or address of sponsor